Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 389 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TAC Clear all
Terminated Phase 2 Interventional

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

NCT00464347
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
Drug · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 22, 2026, 5:30 AM EDT
Recruiting Early Phase 1 Interventional

Efficacy of Intramuscular Steroid Injection for Chronic Cough.

NCT06634823
View directory record Official record
Conditions
Chronic Cough (CC), Laryngeal Disease, Coughing
Interventions
Triamcinolone Acetonide Injectable Suspension, Saline injection
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pudendal Nerve Block in Vaginal Surgery

NCT04198714
View directory record Official record
Conditions
Nerve Block, Pain, Postoperative, Pelvic Floor Disorders, Pelvic Organ Prolapse, Pudendal Neuralgia, Surgery
Interventions
Pudendal block
Procedure
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain

NCT01906944
View directory record Official record
Conditions
Abdominal Pain
Interventions
Bupivacaine 0.25%, Triamcinolone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 22, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 22, 2026, 5:30 AM EDT
Withdrawn Phase 4 Interventional

Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis

NCT03245671
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Kenalog Injectable Product, Decadron Phosphate, Injectable, Epidural Steroid Injection
Drug · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 22, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

NCT07168148
View directory record Official record
Conditions
Nasal Obstruction, Chronic Rhinitis
Interventions
Oxymetazoline + Triamcinolone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

NCT00746889
View directory record Official record
Conditions
Osteoarthritis
Interventions
triamcinolone acetonide, saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2010 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

NCT01080131
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
96
States / cities
Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 22, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery

NCT06734975
View directory record Official record
Conditions
Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
Interventions
Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 22, 2026, 5:30 AM EDT
Terminated Phase 1 Interventional

ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis

NCT04831255
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder, Adhesive Capsulitis of Shoulder
Interventions
triamcinolone acetonide extended-release injectable suspension
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Regimen Optimization Study

NCT02137239
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Thymoglobulin, Belatacept, mycophenolate mofetil(MMF), Corticosteroids, Everolimus(EVL), Tacrolimus(TAC)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

NCT03605927
View directory record Official record
Conditions
Graft-versus-host-disease, GVHD, GVHD, Acute
Interventions
BMS-986004, Sirolimus, Tacrolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Duarte, California • Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 22, 2026, 5:30 AM EDT
Suspended Phase 2 Interventional

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

NCT06680661
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept
Drug · Radiation · Biological
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 5:30 AM EDT
Not listed Phase 4 Interventional

Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue

NCT02398539
View directory record Official record
Conditions
Hypergranulation Tissue; Gastrostomy Tube Site
Interventions
Silver Nitrate, Triamcinolone
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

NCT00768066
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo
Biological
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 22, 2026, 5:30 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT04885972
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
Interventions
Resiniferatoxin, Zilretta, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
La Mesa, California • Pasadena, California • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors

NCT03627741
View directory record Official record
Conditions
Fibromatosis
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis

NCT02242630
View directory record Official record
Conditions
Subacromial Bursitis, Shoulder Pain
Interventions
Methylprednisolone, 20 mg, Methylprednisolone, 40 mg, Triamcinolone, 20 mg, Triamcinolone, 40 mg
Drug
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 22, 2026, 5:30 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

PST/Laser v. Laser Alone for CSME

NCT00229918
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide
Drug
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
25 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2005 · Synced Oct 22, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

NCT02988466
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Haplo HCT ≥55 years old, GVHD Prophylaxis, Haplo HCT ≥55 and < 65 years old, Haplo HCT ≥65 and ≤75 years old
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 22, 2026, 5:30 AM EDT